KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Travere Therapeutics (TVTX) over the last 16 years, with Q3 2025 value amounting to $35.6 million.

  • Travere Therapeutics' Net Cash Flow rose 87050.48% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.8 million, marking a year-over-year increase of 16999.12%. This contributed to the annual value of $1.3 million for FY2024, which is 10049.52% up from last year.
  • Latest data reveals that Travere Therapeutics reported Net Cash Flow of $35.6 million as of Q3 2025, which was up 87050.48% from $11.3 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Net Cash Flow high stood at $91.8 million for Q1 2022, and its period low was -$147.7 million during Q3 2023.
  • Over the past 5 years, Travere Therapeutics' median Net Cash Flow value was -$10.9 million (recorded in 2024), while the average stood at -$18.7 million.
  • Per our database at Business Quant, Travere Therapeutics' Net Cash Flow surged by 127514.6% in 2021 and then crashed by 21610.07% in 2022.
  • Quarter analysis of 5 years shows Travere Therapeutics' Net Cash Flow stood at -$41.6 million in 2021, then tumbled by 169.6% to -$112.2 million in 2022, then rose by 26.8% to -$82.2 million in 2023, then surged by 128.1% to $23.1 million in 2024, then soared by 54.05% to $35.6 million in 2025.
  • Its Net Cash Flow was $35.6 million in Q3 2025, compared to $11.3 million in Q2 2025 and $2.8 million in Q1 2025.